LAZCLUZE Drug Patent Profile

When do Lazcluze patents expire, and what generic alternatives are available?

Lazcluze is a drug marketed by Janssen Biotech and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and sixty-five patent family members in thirty-nine countries.

The generic ingredient in LAZCLUZE is lazertinib mesylate. One supplier is listed for this compound. Additional details are available on the lazertinib mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Lazcluze

Lazcluze will be eligible for patent challenges on August 19, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 18, 2038. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LAZCLUZE

International Patents:	165
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	421
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LAZCLUZE
What excipients (inactive ingredients) are in LAZCLUZE?	LAZCLUZE excipients list
DailyMed Link:	LAZCLUZE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LAZCLUZE

NDA:

219008

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LAZCLUZE

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A4 Inhibitors Kinase Inhibitors

US Patents and Regulatory Information for LAZCLUZE

LAZCLUZE is protected by seven US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No			Y	Y
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No			Y
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-002	Aug 19, 2024		RX	Yes	Yes
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-002	Aug 19, 2024		RX	Yes	Yes

International Patents for LAZCLUZE

When does loss-of-exclusivity occur for LAZCLUZE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Eurasian Patent Organization

European Patent Office

Israel

Japan

Malaysia

Mexico

Morocco

New Zealand

Philippines

Saudi Arabia

Singapore

South Africa

South Korea

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LAZCLUZE around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I664173
Japan	7369769
Australia	2021257662
China	110869367
Japan	2025118606	二重特異性抗ＥＧＦＲ／Ｃ－ＭＥＴ抗体と第３世代ＥＧＦＲチロシンキナーゼ阻害剤との併用療法 (COMBINATION THERAPIES WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES AND THIRD GENERATION EGFR TYROSINE KINASE INHIBITORS)
Lithuania	3207035

Last updated: April 22, 2026

LAZCLUZE: Market dynamics and financial trajectory

What is LAZCLUZE’s market position?

LAZCLUZE is a branded oncology medicine developed and commercialized in the US by Bristol Myers Squibb. Its commercialization footprint is tied to (1) where the drug is approved and reimbursed, (2) payer adoption speed in those indications, and (3) competitive intensity from other targeted and immuno-oncology options in the same treatment pathways.

LAZCLUZE’s market dynamics are driven by a standard oncology adoption curve: rapid early uptake in high-coverage settings, followed by slower growth where utilization management, sequencing decisions, and competing product penetration reduce addressable share.

Which macro forces typically shape demand for LAZCLUZE?

Demand for an oncology biologic like LAZCLUZE is constrained by:

• Indication-specific eligible population size (diagnostic prevalence, stage at treatment, biomarker eligibility, line-of-therapy rules).
• Formulary and reimbursement access (commercial plan inclusion, Medicare coverage behavior, specialty pharmacy routing).
• Treatment sequencing (how clinicians place it relative to IO, TKIs, ADCs, and chemo in practice).
• Site of care economics (hospital outpatient vs community; administration logistics; patient share at specialty centers).

Those forces do not produce a predictable quarter-by-quarter pattern, but they do determine the slope of revenue growth once the initial access wins are reflected.

---

How does pricing and reimbursement affect LAZCLUZE’s adoption?

Pricing power vs payer friction

Oncology pricing generally sustains revenue per treated patient, but adoption depends on net pricing outcomes:

• List-to-net dilution driven by rebates, patient assistance, and payer contracting.
• Prior authorization and step therapy (where used) affecting patient starts.
• Center-of-excellence contracting that concentrates volume into fewer institutions.

If LAZCLUZE has broad formulary coverage and minimal authorization friction in its key indications, the financial trajectory tracks treated-volume growth. If payer controls intensify, the trajectory shifts toward slower starts and higher reliance on retention.

Real-world uptake mechanics

For oncology brands, the first monetization signal usually arrives through:

• Claims-based starts at specialty sites
• Therapy line displacement where clinicians actively switch regimens
• Sustained persistence through on-treatment course durations

That pattern typically shows up in revenue as a ramp early, then deceleration unless new indications or regimen expansions broaden the addressable population.

---

What is LAZCLUZE’s financial trajectory baseline (revenue, growth, and profitability drivers)?

A drug’s financial trajectory is best read through three levers:

1. Volume of treated patients
2. Net revenue per patient (net price)
3. Mix effects (indication mix, line-of-therapy mix, geography)

For LAZCLUZE specifically, the key issue for forecasting and investment-grade tracking is whether its revenue growth is volume-led (strong payer adoption, rising treated counts) or price/mix-led (net price retention with limited incremental patients).

Business model implications

• If LAZCLUZE’s uptake is claims-confirmed across more plans and sites, revenue should trend upward as the treated population expands.
• If uptake is plan-limited or authorization-gated, revenue can still grow initially on high-tier contracts, but later quarters tend to show a flattening profile.

---

Where does competitive pressure come from?

Competitive dynamics in LAZCLUZE’s therapeutic area are usually measured by:

• Number of alternative regimens available at the same line
• Clinical differentiation (response depth, durability, safety profile, biomarker selection)
• Commercial differentiation (access agreements and dosing convenience)
• Patent and exclusivity timelines affecting generic and biosimilar risk

In oncology, the critical competitive variable is not just “what else exists,” but what clinicians switch to when LAZCLUZE faces non-clinical barriers (access delays, administrative burden, or limited reimbursement).

---

What do “events” do to LAZCLUZE’s trajectory?

For oncology brands, revenue step-changes typically coincide with:

• New label expansion (new indication, new biomarker population, new line-of-therapy)
• Guideline changes (NCCN/ESMO adoption, payer policy updates)
• Safety or efficacy updates that alter sequencing confidence
• Contracting cycles (new formulary decisions and renewal outcomes)

Absent new label or guideline shifts, the expected pattern becomes a typical plateau-to-growth arc based on incremental treated starts and replacement of older therapy use.

---

Market dynamics map: what to monitor next

To track LAZCLUZE’s financial trajectory with decision-grade signals, focus on measurable indicators that precede revenue:

Commercial execution signals

• US formulary coverage progression across top commercial insurers and Medicaid managed care
• Specialty pharmacy distribution breadth and patient support program utilization (as a proxy for access friction)
• Institutional adoption (share of treated patients at high-volume centers)

Clinical uptake signals

• Treatment sequencing behavior (share uptake in the expected lines)
• Biomarker eligibility fulfillment trends in real-world settings
• Persistence and dose adherence patterns (linked to administered units)

Competitive and policy signals

• Utilization management tightening by major payers
• New entrants in the same lines (including next-generation ADCs and immunotherapy combinations)
• Biosimilar or generic pressure on comparator regimens that can change the “default switch” decisions

---

Key Takeaways

• LAZCLUZE’s market dynamics follow a standard oncology adoption curve: early volume driven by access wins, later growth shaped by formulary breadth and utilization management.
• Net revenue growth depends on whether increases come from treated-patient starts versus net price retention and mix effects.
• Competitive intensity and sequencing behavior determine whether growth sustains or flattens absent label expansions or guideline shifts.
• The most decision-relevant leading indicators are formulary coverage, specialty pharmacy routing, institutional adoption, and utilization management changes.

---

FAQs

1) What drives LAZCLUZE revenue more: pricing or volume?

LAZCLUZE’s revenue trajectory hinges on treated-patient starts in reimbursed indications. Pricing supports net revenue per patient, but volume controls the overall growth rate in most oncology launches and expansions.

2) How do payer decisions affect LAZCLUZE financials quarter-to-quarter?

Payer formulary inclusion, prior authorization policies, and contracting cycles influence therapy starts with lag. That typically creates a faster ramp after coverage wins and slower growth if utilization management tightens.

3) What competitive factors most impact LAZCLUZE share?

Sequencing choice within the same line of therapy, clinical differentiation that changes switch confidence, and access convenience (routing and admin burden) drive share more than headline efficacy alone.

4) Which events typically create step changes for oncology brands like LAZCLUZE?

New label expansions, guideline uptake, and meaningful safety or efficacy updates that shift sequencing behavior, along with renewal outcomes in payer contracting cycles.

5) What should investors track to validate LAZCLUZE trajectory?

Formulary breadth, specialty pharmacy distribution coverage, institutional adoption at high-volume centers, and persistence metrics that translate into administered units.

---

References (APA)

[1] Bristol Myers Squibb. (n.d.). LAZCLUZE (portfolio information and product pages). https://www.bms.com/
[2] US FDA. (n.d.). Drug approvals and labeling for LAZCLUZE (search results). https://www.fda.gov/
[3] National Comprehensive Cancer Network. (n.d.). NCCN Clinical Practice Guidelines (relevant oncology guideline updates). https://www.nccn.org/